French-American cell and gene collab takes step forward

19 November 2021
vials_biotech_lab_biosimilars_big

In the flourishing field of cell and gene therapies, a collaboration between Floridian oncology firm Cytovia Therapeutics and French biotech Cellectis (Euronext: ALCLS) is advancing.

Cytovia is developing a unique kind of off-the-shelf therapy, derived from gene-edited Natural Killer (NK) cells, while Cellectis has a portfolio of CAR-T cell candidates in multiple indications.

As a range of new technologies come to fruition, analysts have upped expectations for the therapeutic and commercial potential of cell and gene therapies in recent years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology